Nick Pavlakis
A5085372050- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Neuroblastoma Research and Treatments
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Fibroblast Growth Factor Research
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- Pancreatitis Pathology and Treatment
- Medical Imaging and Pathology Studies
- Gastrointestinal Tumor Research and Treatment
Royal North Shore Hospital
2016-2025
The University of Sydney
2016-2025
Northern Sydney Local Health District
2016-2024
Westmead Hospital
2024
St. Leonards Hospital
2024
Sydney Local Health District
2024
Northern Cancer Institute
2015-2023
North Shore Hospital
2010-2022
Hudson Institute
2021-2022
Genesis HealthCare
2022
Purpose Human epidermal growth factor receptor 2 ( HER2, ERBB2)-activating mutations occur in 2% of lung cancers. We assessed the activity ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, cohort patients with HER2-mutant cancers as part phase II basket trial. Patients and Methods received emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria Solid Tumors (RECIST) version 1.1....
Asbestos-induced chronic inflammation is implicated in the pathogenesis of malignant mesothelioma (MM). We have investigated blood neutrophil-to-lymphocyte ratio (NLR), an index systemic inflammation, as a prognostic factor MM patients.Patients with who had therapy at participating institutes were studied. Potential factors such age, gender, performance status, histologic subtype, and baseline laboratory parameters, including NLR, analyzed. Overall survival from commencement was determined...
The study aims to investigate the prognostic value of lymphocyte-to-monocyte ratio (LMR) in patients with colorectal cancer (CRC) undergoing curative resection and compare it established biomarkers including neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), modified Glasgow score (mGPS), combined BRAF-mismatch repair (MMR) status.The significance systemic inflammatory markers CRC such as NLR, PLR, mGPS has been well defined. Commonly used genetic BRAF-MMR status have also found...
Abstract Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical models and cancer patients. The 12 HGSOC patient-derived xenografts (PDX) the rucaparib was assessed, variable dose-dependent responses observed chemo-naive BRCA1/2 -mutated PDX, no PDX...
Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours.Most reports documented the sensitivity specificity of each radiopharmaceutical independently, even suggested superiority one over other for different grades disease.Aim: The aim this work was develop a grading scheme that describes joint results in staging subjects with tumours single combined parameter.The has developed is referred as NETPET grade.Methods: This...
Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices International Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets patients with aberrations their tumor that could be targeted currently available therapies.
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
This randomized, open-label trial compared the efficacy and safety of adjuvant
Abstract The lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance this crosslinking and stabilizing fibrillar collagens its known role tumor desmoplasia. Using small-molecule drug-design approaches, we generated validated PXS-5505, first-in-class highly selective potent pan-lysyl inhibitor. We demonstrate vitro vivo that inhibition decreases chemotherapy-induced pancreatic desmoplasia stiffness, reduces cancer cell invasion metastasis,...
PURPOSE Although checkpoint inhibitors have improved first-line treatment for non–small cell lung cancer (NSCLC), a therapeutic need remains patients whose disease does not respond or who experience progression after anti–PD-L1/PD-1 immunotherapy. CONTACT-01 (ClinicalTrials.gov identifier: NCT04471428 ) evaluated atezolizumab plus cabozantinib versus docetaxel in with metastatic NSCLC developed concurrent sequential and platinum-containing chemotherapy. METHODS This multicenter, open-label,...
Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets EGFR exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC. Patients with treatment-naive locally NSCLC were randomly assigned 1:1 to 160 mg once daily or...
BackgroundSubstantial numbers of cancer patients use complementary medicine therapies, even without a supportive evidence base. This study aimed to evaluate in randomized controlled trial, the Medical Qigong (MQ) compared with usual care improve quality life (QOL) patients.Patients and methodsOne hundred sixty-two range cancers were recruited. QOL fatigue measured by Functional Assessment Cancer Therapy—General Therapy—Fatigue, respectively, mood status Profile Mood State. The inflammatory...
BACKGROUND Pulmonary toxicity reported with gemcitabine is usually mild and self-limiting. The authors report a series of three patients who had life-threatening pulmonary after receiving gemcitabine. METHODS presented to two major teaching hospitals significant dysfunction while Case data were obtained from patient records. A review the literature was done seek reports cytosine arabinoside (ara-C). RESULTS common features respiratory illnesses in this study tachypnea, marked hypoxemia, an...